

Astellas Announces Revision of Dividend Forecast (Increase Dividends) for FY2014 ending March 31, 2015

Tokyo, October 31, 2014 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to revise its dividend forecast for fiscal year 2014 (FY2014), ending March 2015 as below:

Particulars

1. Reasons for Revision

The Company is working aggressively towards increasing corporate value on a continual basis and, as a consequence, improving its return to shareholders. While prioritizing business investment to assure future growth, the Company will strive to increase dividend payments stably and continuously, taking into consideration the dividend on equity attributable to owners of parent (DOE) and other factors based on medium- to long-term profit growth on a consolidated basis. Further, the Company will flexibly acquire its own shares to further increase capital efficiency and shareholder return.

In accordance with the above profit distribution policy, after considering factors that include earnings forecasts and financial condition for the current fiscal year, the Company revised its year-end dividend forecast to ¥16 per share, an increase of ¥1 compared to the previous forecast (announced on May 12, 2014). As a result, the annual dividend was revised to ¥30 per share (including interim dividend of ¥14 per share) to shareholders.

2. Details for the Revision

	Dividends per share (yen)		
	Interim	Year-end	Annual Total
Previous forecast (Announced on May 12, 2014)	14.00	15.00	29.00
Revised forecast	-	16.00	30.00
Actual for FY2014 ending March 31,2015	14.00	-	-
Actual for FY2013* ending March 31,2014	65.00	70.00	135.00

*The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014. Dividends per share written here is the actual figure before the April 1, 2014 stock split. Dividends per share is calculated based on the assumption that the stock split was conducted at the beginning of FY2013 will be 13.00 (interim), 14.00 (year-end) and 27.00 (annual total).

#####

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en